Get the app
US › Healthcare

Neurosense Therapeutics Ltd (NRSN)

US · Healthcare · Biotechnology

$1.68+20.43%
Last close · 2026-11-06

Key statistics

Market cap
$2.7M
Forward P/E
0.0
P/B
2.64
Book value
$-0.96
EPS (TTM)
$-47.10
52-week high
$25.40
52-week low
$1.10
50-day MA
$5.07
200-day MA
$12.59
Beta
1.72

Analyst view

Analysts rate Neurosense Therapeutics Ltd a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $78.50.

Shareholding

Insiders
31.42%
Institutions
1.08%

Largest institutional holders

FundStake
UBS Group AG0.29%
Independent Advisor Alliance0.26%
Yorkville Advisors Global, LP0.21%
Commonwealth Equity Services, LLC0.06%
PNC Financial Services Group Inc0.06%
Pathstone Holdings LLC0.04%
Geode Capital Management, LLC0.04%
XTX Topco Ltd0.03%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neurosense Therapeutics Ltd — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.